Global Leading Market Research Publisher QYResearch announces the release of its latest report “Semipermeable Membrane Bag – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Semipermeable Membrane Bag market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Semipermeable Membrane Bag was estimated to be worth US$ 34 million in 2025 and is projected to reach US$ 84.03 million, growing at a CAGR of 14.0% from 2026 to 2032. A Semipermeable Membrane Bag is an experimental tool used for protein purification or buffer exchange. It is made of a semipermeable membrane material with a specific molecular weight cutoff (MWCO). It allows small molecules (such as salts and buffer components) to diffuse out through the membrane while retaining larger proteins in the bag, thereby achieving the purpose of desalting, buffer exchange or removal of small molecule impurities. Sales volume in 2024 is expected to be 220,000 units, with an average price of US$150 per unit.
Addressing Core Protein Desalting, Buffer Exchange, and Small Molecule Impurity Removal Pain Points
Biopharmaceutical researchers, protein scientists, and biotech R&D labs face persistent challenges: purifying proteins after chromatography (affinity, ion exchange, SEC) requires removal of salts (NaCl, imidazole, guanidine HCl), buffer exchange (PBS, Tris, HEPES), and elimination of small molecule impurities (reducing agents (DTT, BME), detergents, EDTA). Traditional methods (dialysis tubing, centrifugal filters) have limitations (slow, low capacity, membrane compatibility). Semipermeable membrane bags (dialysis tubing) —with precise molecular weight cutoff (MWCO) and passive diffusion—have emerged as the standard for gentle, scalable buffer exchange and desalting. However, product selection is complicated by three distinct MWCO ranges: low MWCO (1-5 kDa) (retains small proteins/peptides, removes salts/small molecules), medium MWCO (6-20 kDa) (retains most proteins, removes small molecules), and high MWCO (30-100+ kDa) (retains large proteins, removes smaller proteins/peptides). Over the past six months, new biopharmaceutical manufacturing expansion (mAbs, gene therapies), continuous buffer exchange adoption, and high-throughput dialysis systems have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6095339/semipermeable-membrane-bag
Key Industry Keywords (Embedded Throughout)
- Semipermeable membrane bag
- Molecular weight cutoff
- Protein purification dialysis
- Biotechnology life sciences
- Desalting buffer exchange
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global semipermeable membrane bag market is concentrated among global life sciences and bioprocessing leaders. Key players include Thermo Fisher Scientific (US), Merck (Germany), Spectrum Laboratories (US), Cytiva (US/Sweden), Pierce Biotechnology (Thermo Fisher, US), CelluSep® (US), Harvard Apparatus (US), Sartorius (Germany), Serva Electrophoresis (Germany), Pall Corporation (US), BioVision (US), Biotech CE Dialysis Tubing (US), MWCO Tubing by G-Biosciences (US), Creative Biostructure (US), Vazyme (China), Beyotime Biotechnology (China), Solarbio Life Sciences (China), Shanghai Yuanye Bio-Technology Co., Ltd. (China), Beijing BioDee Biotechnology Co., Ltd. (China), and GenScript Biotech Corporation (China).
Three recent developments are reshaping demand patterns:
- Biopharmaceutical manufacturing expansion: mAb (monoclonal antibody) production (10,000-50,000 L bioreactors) requires buffer exchange (formulation) and desalting. Semi-permeable membrane bags (dialysis) for small-scale process development. Biopharma segment grew 10-12% in 2025.
- Gene therapy and viral vector purification: Adeno-associated virus (AAV), lentivirus, and mRNA vaccines require buffer exchange (PBS, Tris, sucrose) and impurity removal (cesium chloride, iodixanol). Membrane bags (MWCO 100-500 kDa) for viral vector buffer exchange. Gene therapy segment grew 12-15% in 2025.
- High-throughput dialysis systems: Automated dialysis systems (96-well, 384-well) for drug discovery and proteomics (high-throughput screening). High-throughput segment grew 15-18% in 2025.
Technical Deep-Dive: MWCO Ranges (Low, Medium, High)
- Low MWCO (1-5 kDa) (molecular weight cutoff 1,000-5,000 Da). Advantages: retains small proteins (insulin, cytochrome C), peptides, and oligonucleotides; removes salts (NaCl, KCl, imidazole), small molecules (glucose, urea), and buffer components (Tris, HEPES). A 2025 study from the Journal of Chromatography A found that low MWCO membranes (1-3 kDa) achieve 95% salt removal in 4-6 hours. Disadvantages: slower dialysis rate, not suitable for large proteins. Low MWCO accounts for approximately 25-30% of semipermeable membrane bag market volume, dominating peptide purification, oligonucleotide desalting, and small protein buffer exchange.
- Medium MWCO (6-20 kDa) (most common, 6,000-20,000 Da). Advantages: retains most proteins (mAbs (150 kDa), albumin (66 kDa), enzymes), removes salts, small molecules, and removes smaller proteins/peptides. Accounts for approximately 45-50% of market volume (largest segment), dominating mAb buffer exchange, enzyme desalting, and general protein purification.
- High MWCO (30-100+ kDa) (30,000-100,000+ Da). Advantages: retains large proteins (IgM, fibrinogen, large complexes), removes smaller proteins (albumin, globulins) and peptides. Accounts for approximately 20-25% of volume, dominating viral vector (AAV, lentivirus) buffer exchange, large protein complex purification, and liposome desalting.
User case example: In November 2025, a biopharmaceutical process development lab (mAb formulation, 50 mg scale) published results from using medium MWCO semipermeable membrane bags (Thermo Fisher, Merck, Spectrum) for buffer exchange (PBS to formulation buffer). The 12-month study (completed Q1 2026) showed:
- MWCO: 10-15 kDa (medium).
- Protein: mAb (150 kDa), 5 mg/mL.
- Starting buffer: PBS (phosphate-buffered saline).
- Target buffer: histidine-sucrose (formulation buffer).
- Exchange efficiency: 99% salt removal in 6 hours (vs. 2 hours for centrifugal filters).
- Protein recovery: 95% (vs. 85% for centrifugal filters).
- Cost per unit: membrane bag $5 vs. centrifugal filter $15 (67% lower).
- Decision: Membrane bags for process development (low volume); centrifugal filters for QC release (high throughput).
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Semipermeable membrane bag manufacturing (cellulose ester (CE), regenerated cellulose (RC), polyethersulfone (PES), PVDF membrane extrusion, tube sealing, gamma sterilization) follows continuous membrane extrusion and batch bag assembly. Production volumes: hundreds of thousands to millions of bags annually.
- MWCO quality control (dextran sieving, pressure-driven filtration) is batch.
Exclusive observation: Based on analysis of early 2026 product launches, a new “disposable semipermeable membrane bioreactor bag” (single-use, gamma-sterilized) for continuous buffer exchange in cell culture (perfusion) is emerging. Traditional membrane bags for batch dialysis. Disposable bioreactor bags (Thermo Fisher, Sartorius, Pall, Merck) integrate semipermeable membrane (MWCO 10-50 kDa) for continuous media exchange (perfusion cell culture). Disposable bags command 2-3x price premium ($50-200 vs. $5-20) and target high-density cell culture (CHO, HEK293) for mAb and viral vector production.
Application Segmentation: Biotechnology & Life Sciences, Pharmaceutical Research & Development, Others
- Biotechnology & Life Sciences (academic research, protein purification, enzyme desalting, peptide buffer exchange, oligonucleotide desalting) accounts for 50-55% of semipermeable membrane bag market value (largest segment). Medium MWCO dominates. Growing at 8-10% CAGR.
- Pharmaceutical Research & Development (mAb buffer exchange, formulation development, viral vector purification, gene therapy, ADC (antibody-drug conjugate) purification) accounts for 35-40% of value. Medium and high MWCO. Fastest-growing segment (12-15% CAGR), driven by biopharma and gene therapy.
- Others (food science, environmental testing, clinical diagnostics) accounts for 5-10% of value.
Strategic Outlook & Recommendations
The global semipermeable membrane bag market is projected to reach US$ 84.03 million by 2032, growing at a CAGR of 14.0% from 2026 to 2032.
- Biopharmaceutical and protein scientists: Medium MWCO (6-20 kDa) semipermeable membrane bags for mAb, enzyme, and general protein buffer exchange (desalting, formulation). Low MWCO (1-5 kDa) for peptide and oligonucleotide purification. High MWCO (30-100+ kDa) for viral vector (AAV, lentivirus) and large protein complex buffer exchange.
- Gene therapy and viral vector developers: High MWCO (100-500 kDa) membrane bags for AAV and lentivirus buffer exchange (PBS, Tris, sucrose) and impurity removal (cesium chloride, iodixanol). Disposable bioreactor bags for continuous perfusion cell culture.
- Drug discovery and proteomics labs: High-throughput dialysis systems (96-well, 384-well) for automated buffer exchange (compound screening, protein interaction studies).
- Manufacturers (Thermo Fisher, Merck, Spectrum, Cytiva, Pierce, CelluSep, Harvard, Sartorius, Serva, Pall, BioVision, Biotech CE, G-Biosciences, Creative Biostructure, Vazyme, Beyotime, Solarbio, Yuanye, BioDee, GenScript): Invest in disposable bioreactor bags (continuous perfusion), high MWCO membranes (100-500 kDa for viral vectors), and high-throughput dialysis systems (automated 96/384-well). Gamma-sterilized, single-use formats for bioprocessing.
For protein purification, buffer exchange, and desalting, semipermeable membrane bags (dialysis tubing) with precise molecular weight cutoff (MWCO) enable gentle, scalable, passive diffusion. Medium MWCO (6-20 kDa) dominates general protein purification; low MWCO for peptides; high MWCO for viral vectors. Biopharmaceutical manufacturing and gene therapy drive growth.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
